Le informazioni sugli articoli di fonte ISI sono coperte da copyright

Per ulteriori informazioni selezionare i riferimenti di interesse.

1. Castilleja, A; Ward, NE; O'Brian, CA; Swearingen, B; Swan, E; Gillogly, MA; Murray, JL; Kudelka, AP; Gershenson, DM; Ioannides, CG
   Accelerated HER-2 degradation enhanced ovarian tumor recognition by CTL. Implications for tumor immunogenicity
   MOLECULAR AND CELLULAR BIOCHEMISTRY
   
   A. Castilleja et al., "Accelerated HER-2 degradation enhanced ovarian tumor recognition by CTL. Implications for tumor immunogenicity", MOL C BIOCH, 217(1-2), 2001, pp. 21-33
2. Murray, JL; Hudson, JM; Ross, MI; Zhang, HZ; Ioannides, CG
   Reduced recognition of metastatic melanoma cells by autologous MART-1 specific CTL: Relationship to TAP expression
   JOURNAL OF IMMUNOTHERAPY
   
   J.L. Murray et al., "Reduced recognition of metastatic melanoma cells by autologous MART-1 specific CTL: Relationship to TAP expression", J IMMUNOTH, 23(1), 2000, pp. 28-35
3. Lee, TV; Kim, DK; Peoples, GE; Castilleja, A; Murray, JL; Gershenson, DM; Ioannides, CG
   Secretion of CXC chemokine IP-10 by peripheral blood mononuclear cells from healthy donors and breast cancer patients stimulated with HER-2 peptides
   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
   
   T.V. Lee et al., "Secretion of CXC chemokine IP-10 by peripheral blood mononuclear cells from healthy donors and breast cancer patients stimulated with HER-2 peptides", J INTERF CY, 20(4), 2000, pp. 391-401
4. Anderson, BW; Peoples, GE; Murray, JL; Gillogly, MA; Gershenson, DM; Ioannides, CG
   Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals
   CLINICAL CANCER RESEARCH
   
   B.W. Anderson et al., "Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals", CLIN CANC R, 6(11), 2000, pp. 4192-4200
5. Lee, TV; Anderson, BW; Peoples, GE; Castilleja, A; Murray, JL; Gershenson, DM; Ioannides, CG
   Identification of activated tumor antigen-reactive CD8(+) cells in healthyindividuals
   ONCOLOGY REPORTS
   
   T.V. Lee et al., "Identification of activated tumor antigen-reactive CD8(+) cells in healthyindividuals", ONCOL REP, 7(3), 2000, pp. 455-466
6. Yen, N; Ioannides, CG; Xu, K; Swisher, SG; Lawrence, DD; Kemp, BL; El-Naggar, AK; Cristiano, RJ; Fang, BL; Glisson, BS; Hong, WK; Khuri, FR; Kurie, JM; Lee, JJ; Lee, JS; Merritt, JA; Mukhopadhyay, T; Nesbitt, JC; Nguyen, D; Perez-Soler, R; Pisters, KMW; Putnam, JB; Schrump, DS; Shin, DM; Walsh, GL; Roth, JA
   Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type p53 (Ad-p53)
   CANCER GENE THERAPY
   
   N. Yen et al., "Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type p53 (Ad-p53)", CANC GENE T, 7(4), 2000, pp. 530-536
7. Anderson, RW; Kudelka, AP; Honda, T; Pollack, MS; Gershenson, DM; Gillogly, MA; Murray, JL; Ioannides, CG
   Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides
   CANCER IMMUNOLOGY IMMUNOTHERAPY
   
   R.W. Anderson et al., "Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides", CANCER IMMU, 49(9), 2000, pp. 459-468
8. Murray, JL; Przepiorka, D; Ioannides, CG
   Clinical trials of HER-2/neu-specific vaccines
   SEMINARS IN ONCOLOGY
   
   J.L. Murray et al., "Clinical trials of HER-2/neu-specific vaccines", SEMIN ONCOL, 27(6), 2000, pp. 71-75
9. Ward, NE; Stewart, JR; Ioannides, CG; O'Brian, CA
   Oxidant-induced S-gutathiolation inactivates protein kinase C-alpha (PKC-alpha): A potential mechanism of PKC isozyme regulation
   BIOCHEMISTRY
   
   N.E. Ward et al., "Oxidant-induced S-gutathiolation inactivates protein kinase C-alpha (PKC-alpha): A potential mechanism of PKC isozyme regulation", BIOCHEM, 39(33), 2000, pp. 10319-10329
10. Peoples, GE; Anderson, BW; Lee, TV; Murray, JL; Kudelka, AP; Wharton, JT; Ioannides, CG
    Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers
    CLINICAL CANCER RESEARCH
    
    G.E. Peoples et al., "Vaccine implications of folate binding protein, a novel cytotoxic T lymphocyte-recognized antigen system in epithelial cancers", CLIN CANC R, 5(12), 1999, pp. 4214-4223
11. Anderson, LD; Hudson, JM; Savary, CA; Fisk, B; Gershenson, DM; Ioannides, CG
    HER-2/neu peptide specificity in the recognition of HLA-A2 by natural killer cells
    CANCER IMMUNOLOGY IMMUNOTHERAPY
    
    L.D. Anderson et al., "HER-2/neu peptide specificity in the recognition of HLA-A2 by natural killer cells", CANCER IMMU, 48(7), 1999, pp. 401-410
12. Kim, DK; Lee, TV; Castilleja, A; Anderson, BW; Peoples, GE; Kudelka, AP; Murray, JL; Sittisomwong, T; Wharton, JT; Kim, JW; Ioannides, CG
    Folate binding protein peptide 191-199 presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients
    ANTICANCER RESEARCH
    
    D.K. Kim et al., "Folate binding protein peptide 191-199 presented on dendritic cells can stimulate CTL from ovarian and breast cancer patients", ANTICANC R, 19(4B), 1999, pp. 2907-2916
13. Stewart, JR; Ward, NE; Ioannides, CG; O'Brian, CA
    Resveratrol preferentially inhibits protein kinase C-catalyzed phosphorylation of a cofactor-independent, arginine-rich protein substrate by a novel mechanism
    BIOCHEMISTRY
    
    J.R. Stewart et al., "Resveratrol preferentially inhibits protein kinase C-catalyzed phosphorylation of a cofactor-independent, arginine-rich protein substrate by a novel mechanism", BIOCHEM, 38(40), 1999, pp. 13244-13251
14. HUDSON JM; CASTILLEJA A; MURRAY JL; HONDA T; KUDELKA A; SINGLETARY E; WHARTON JT; IOANNIDES CG
    GROWTH AND ANTIGEN RECOGNITION OF TUMOR-INFILTRATING LYMPHOCYTES FROMHUMAN BREAST-CANCER
    Journal of interferon & cytokine research
    
    J.M. Hudson et al., "GROWTH AND ANTIGEN RECOGNITION OF TUMOR-INFILTRATING LYMPHOCYTES FROMHUMAN BREAST-CANCER", Journal of interferon & cytokine research, 18(7), 1998, pp. 529-536
15. TUTTLE TM; ANDERSON BW; THOMPSON WE; LEE JE; SAHIN A; SMITH TL; GRABSTEIN KH; WHARTON JT; IOANNIDES CG; MURRAY JL
    PROLIFERATIVE AND CYTOKINE RESPONSES TO CLASS-II HER-2 NEU-ASSOCIATEDPEPTIDES IN BREAST-CANCER PATIENTS/
    Clinical cancer research
    
    T.M. Tuttle et al., "PROLIFERATIVE AND CYTOKINE RESPONSES TO CLASS-II HER-2 NEU-ASSOCIATEDPEPTIDES IN BREAST-CANCER PATIENTS/", Clinical cancer research, 4(8), 1998, pp. 2015-2024
16. Peoples, GE; Anderson, BW; Fisk, B; Kudelka, AP; Wharton, JT; Ioannides, CG
    Ovarian cancer-associated lymphocyte recognition of folate binding proteinpeptides
    ANNALS OF SURGICAL ONCOLOGY
    
    G.E. Peoples et al., "Ovarian cancer-associated lymphocyte recognition of folate binding proteinpeptides", ANN SURG O, 5(8), 1998, pp. 743-750
17. CASTILLEJA A; OBRIAN CA; ANDERSON BW; WHARTON JT; IOANNIDES CG
    INHIBITION OF CTL EPITOPE PRESENTATION AND TUMOR IMMUNOGENICITY BY HER-2 TYROSINE PHOSPHORYLATION
    The FASEB journal
    
    A. Castilleja et al., "INHIBITION OF CTL EPITOPE PRESENTATION AND TUMOR IMMUNOGENICITY BY HER-2 TYROSINE PHOSPHORYLATION", The FASEB journal, 12(4), 1998, pp. 1684-1684
18. Babcock, B; Anderson, BW; Papayannopoulos, I; Castilleja, A; Murray, JL; Stifani, S; Kudelka, AP; Wharton, JT; Ioannides, CG
    Ovarian and breast cytotoxic T lymphocytes can recognize peptides from theamino enhancer of split protein of the Notch complex
    MOLECULAR IMMUNOLOGY
    
    B. Babcock et al., "Ovarian and breast cytotoxic T lymphocytes can recognize peptides from theamino enhancer of split protein of the Notch complex", MOL IMMUNOL, 35(17), 1998, pp. 1121-1133
19. FISK B; IOANNIDES CG
    INCREASED SENSITIVITY OF ADRIAMYCIN-SELECTED TUMOR LINES TO CTL-MEDIATED LYSIS RESULTS IN ENHANCED DRUG-SENSITIVITY
    Cancer research
    
    B. Fisk e C.G. Ioannides, "INCREASED SENSITIVITY OF ADRIAMYCIN-SELECTED TUMOR LINES TO CTL-MEDIATED LYSIS RESULTS IN ENHANCED DRUG-SENSITIVITY", Cancer research, 58(21), 1998, pp. 4790-4793
20. FISK B; DAGUE B; SEIFERT WE; KUDELKA AP; WHARTON JT; MURRAY JL; IOANNIDES CG
    MASS-SPECTROMETRIC ANALYSIS OF NATURALLY PROCESSED PEPTIDES RECOGNIZED BY OVARIAN TUMOR-ASSOCIATED CD8(+) CTL
    International journal of oncology
    
    B. Fisk et al., "MASS-SPECTROMETRIC ANALYSIS OF NATURALLY PROCESSED PEPTIDES RECOGNIZED BY OVARIAN TUMOR-ASSOCIATED CD8(+) CTL", International journal of oncology, 10(1), 1997, pp. 159-169
21. FISK B; HUDSON M; KAVANAGH J; WHARTON JT; MURRAY JL; IOANNIDES CG; KUDELKA AP
    EXISTENT PROLIFERATIVE RESPONSES OF PERIPHERAL-BLOOD MONONUCLEAR-CELLS FROM HEALTHY DONORS AND OVARIAN-CANCER PATIENTS TO HER-2 PEPTIDES
    Anticancer research
    
    B. Fisk et al., "EXISTENT PROLIFERATIVE RESPONSES OF PERIPHERAL-BLOOD MONONUCLEAR-CELLS FROM HEALTHY DONORS AND OVARIAN-CANCER PATIENTS TO HER-2 PEPTIDES", Anticancer research, 17(1A), 1997, pp. 45-53
22. TUTTLE TM; THOMPSON WE; ANDERSON BW; LEE JE; GRABSTEIN KW; MURRAY JL; WHARTON JT; IOANNIDES CG
    HER-2 NEU PEPTIDE INDUCES TH1 RESPONSES IN ASSOCIATION WITH HLA-DR4 IN BREAST-CANCER PATIENTS/
    Journal of allergy and clinical immunology
    
    T.M. Tuttle et al., "HER-2 NEU PEPTIDE INDUCES TH1 RESPONSES IN ASSOCIATION WITH HLA-DR4 IN BREAST-CANCER PATIENTS/", Journal of allergy and clinical immunology, 99(1), 1997, pp. 188-188
23. FISK B; ANDERSON BW; GRAVITT KR; OBRIAN CA; KUDELKA AP; MURRAY JL; WHARTON JT; IOANNIDES CG
    IDENTIFICATION OF NATURALLY PROCESSED HUMAN OVARIAN PEPTIDES RECOGNIZED BY TUMOR-ASSOCIATED CD8(-LYMPHOCYTES() CYTOTOXIC T)
    Cancer research
    
    B. Fisk et al., "IDENTIFICATION OF NATURALLY PROCESSED HUMAN OVARIAN PEPTIDES RECOGNIZED BY TUMOR-ASSOCIATED CD8(-LYMPHOCYTES() CYTOTOXIC T)", Cancer research, 57(1), 1997, pp. 87-93
24. IOANNIDES CG; FISK B; MELICHAR B; ANDERSON B; STIFANI S; PAPAYANNOPOULOS CG; MURRAY JL; KUDELKA A; WHARTON JT
    OVARIAN AND BREAST CYTOTOXIC LYMPHOCYTES CAN RECOGNIZE PEPTIDES FROM THE AES PROTEIN OF THE NOTCH COMPLEX
    The FASEB journal
    
    C.G. Ioannides et al., "OVARIAN AND BREAST CYTOTOXIC LYMPHOCYTES CAN RECOGNIZE PEPTIDES FROM THE AES PROTEIN OF THE NOTCH COMPLEX", The FASEB journal, 10(6), 1996, pp. 2519-2519
25. FISK B; DAGUE B; SEIFERT WE; LAMBRIS JD; PAPAYANNOPOULOS I; KUDELKA A; WHARTON JT; IOANNIDES CG
    OVARIAN CYTOTOXIC T-LYMPHOCYTES CAN RECOGNIZE COMMON PEPTIDES PRESENTED BY HLA-A2+ TUMORS
    The FASEB journal
    
    B. Fisk et al., "OVARIAN CYTOTOXIC T-LYMPHOCYTES CAN RECOGNIZE COMMON PEPTIDES PRESENTED BY HLA-A2+ TUMORS", The FASEB journal, 10(6), 1996, pp. 2707-2707
26. MELICHAR B; HUDSON JM; HONDA T; TUTTLE T; MURRAY JL; WHARTON JT; IOANNIDES CG
    CHARACTERIZATION OF ANTIGEN RECOGNITION IN TUMOR-INFILTRATING LYMPHOCYTES IN BREAST-CANCER
    The FASEB journal
    
    B. Melichar et al., "CHARACTERIZATION OF ANTIGEN RECOGNITION IN TUMOR-INFILTRATING LYMPHOCYTES IN BREAST-CANCER", The FASEB journal, 10(6), 1996, pp. 2713-2713
27. FISK B; SAVARY C; HUDSON JM; OBRIAN CA; MURRAY JL; WHARTON JT; IOANNIDES CG
    CHANGES IN AN HER-2 PEPTIDE UP-REGULATING HLA-A2 EXPRESSION AFFECT BOTH CONFORMATIONAL EPITOPES AND CTL RECOGNITION - IMPLICATIONS FOR OPTIMIZATION OF ANTIGEN PRESENTATION AND TUMOR-SPECIFIC CTL INDUCTION
    Journal of immunotherapy with emphasis on tumor immunology
    
    B. Fisk et al., "CHANGES IN AN HER-2 PEPTIDE UP-REGULATING HLA-A2 EXPRESSION AFFECT BOTH CONFORMATIONAL EPITOPES AND CTL RECOGNITION - IMPLICATIONS FOR OPTIMIZATION OF ANTIGEN PRESENTATION AND TUMOR-SPECIFIC CTL INDUCTION", Journal of immunotherapy with emphasis on tumor immunology, 18(4), 1995, pp. 197-209
28. BLEVINS TL; FISK B; WHARTON JT; KAVANAGH JJ; IOANNIDES CG; KUDELKA AP
    T-CELL PROLIFERATING RESPONSES TO HER-2 PEPTIDE ANALOGS IN OVARIAN-CANCER PATIENTS
    The FASEB journal
    
    T.L. Blevins et al., "T-CELL PROLIFERATING RESPONSES TO HER-2 PEPTIDE ANALOGS IN OVARIAN-CANCER PATIENTS", The FASEB journal, 9(4), 1995, pp. 800-800
29. FISK B; BLEVINS TL; WHARTON JR; IOANNIDES CG
    IDENTIFICATION OF AN IMMUNODOMINANT PEPTIDE OF HER-2 RECOGNIZED BY OVARIAN TUMOR-SPECIFIC CTL
    The FASEB journal
    
    B. Fisk et al., "IDENTIFICATION OF AN IMMUNODOMINANT PEPTIDE OF HER-2 RECOGNIZED BY OVARIAN TUMOR-SPECIFIC CTL", The FASEB journal, 9(4), 1995, pp. 1023-1023
30. FISK B; FLYTZANIS CN; POLLACK MS; WHARTON JT; IOANNIDES CG
    CHARACTERIZATION OF T-CELL RECEPTOR-V-BETA REPERTOIRE IN OVARIAN TUMOR-REACTING CD3(-) CTL LINES (VOL 40, PG 591, 1994)() CD8(+) CD4()
    Scandinavian journal of immunology
    
    B. Fisk et al., "CHARACTERIZATION OF T-CELL RECEPTOR-V-BETA REPERTOIRE IN OVARIAN TUMOR-REACTING CD3(-) CTL LINES (VOL 40, PG 591, 1994)() CD8(+) CD4()", Scandinavian journal of immunology, 41(1), 1995, pp. 102-102
31. FISK B; BLEVINS TL; WHARTON JT; IOANNIDES CG
    IDENTIFICATION OF AN IMMUNODOMINANT PEPTIDE OF HER-2 NEU PROTOONCOGENE RECOGNIZED BY OVARIAN TUMOR-SPECIFIC CYTOTOXIC T-LYMPHOCYTE LINES/
    The Journal of experimental medicine
    
    B. Fisk et al., "IDENTIFICATION OF AN IMMUNODOMINANT PEPTIDE OF HER-2 NEU PROTOONCOGENE RECOGNIZED BY OVARIAN TUMOR-SPECIFIC CYTOTOXIC T-LYMPHOCYTE LINES/", The Journal of experimental medicine, 181(6), 1995, pp. 2109-2117
32. FISK B; IOANNIDES CG; AGGARWAL S; WHARTON JT; OBRIAN CA; RESTIFO N; GLISSON BS
    ENHANCED EXPRESSION OF HLA-A,B,C AND INDUCIBILITY OF TAP-1, TAP-2, AND HLA-A,B,C BY INTERFERON-GAMMA IN A MULTIDRUG-RESISTANT SMALL-CELL LUNG-CANCER LINE
    Lymphokine and cytokine research
    
    B. Fisk et al., "ENHANCED EXPRESSION OF HLA-A,B,C AND INDUCIBILITY OF TAP-1, TAP-2, AND HLA-A,B,C BY INTERFERON-GAMMA IN A MULTIDRUG-RESISTANT SMALL-CELL LUNG-CANCER LINE", Lymphokine and cytokine research, 13(2), 1994, pp. 125-131
33. FREEDMAN RS; BOWEN JM; DELCOS L; EDWARDS CL; WALLACE S; ATKINSON EN; IOANNIDES CG; KASI LP; SCOTT W; PATENIA R
    ACTIVE INTRALYMPHATIC IMMUNOTHERAPY OF UTERINE CERVICAL-CARCINOMA WITH VIRAL ONCOLYSATE - A PILOT-STUDY
    International journal of gynecological cancer
    
    R.S. Freedman et al., "ACTIVE INTRALYMPHATIC IMMUNOTHERAPY OF UTERINE CERVICAL-CARCINOMA WITH VIRAL ONCOLYSATE - A PILOT-STUDY", International journal of gynecological cancer, 4(2), 1994, pp. 101-110
34. FISK B; CHESAK B; IOANNIDES MG; WHARTON JT; IOANNIDES CG
    SEQUENCE MOTIFS OF HUMAN HER-2 PROTOONCOGENE IMPORTANT FOR PEPTIDE BINDING TO HLA-A2
    International journal of oncology
    
    B. Fisk et al., "SEQUENCE MOTIFS OF HUMAN HER-2 PROTOONCOGENE IMPORTANT FOR PEPTIDE BINDING TO HLA-A2", International journal of oncology, 5(1), 1994, pp. 51-63
35. FISK B; FLYTZANES CN; POLLACK MS; WHARTON JT; IOANNIDES CG
    CHARACTERIZATION OF T-CELL RECEPTOR V-BETA REPERTOIRE IN OVARIAN TUMOR-REACTING CD3(-) CTL LINES()CD8(+)CD4()
    Scandinavian journal of immunology
    
    B. Fisk et al., "CHARACTERIZATION OF T-CELL RECEPTOR V-BETA REPERTOIRE IN OVARIAN TUMOR-REACTING CD3(-) CTL LINES()CD8(+)CD4()", Scandinavian journal of immunology, 40(6), 1994, pp. 591-600
36. FISK B; CHESAK B; POLLACK MS; WHARTON JT; IOANNIDES CG
    OLIGOPEPTIDE INDUCTION OF A CYTOTOXIC T-LYMPHOCYTE RESPONSE TO HER-2 NEU PROTOONCOGENE IN-VITRO/
    Cellular immunology
    
    B. Fisk et al., "OLIGOPEPTIDE INDUCTION OF A CYTOTOXIC T-LYMPHOCYTE RESPONSE TO HER-2 NEU PROTOONCOGENE IN-VITRO/", Cellular immunology, 157(2), 1994, pp. 415-427
37. FISK B; FLYTZANIS CN; TUCKER SL; IOANNIDES CG
    DISSIMILAR TCR V-BETA FREQUENCIES IN TIL FROM DIFFERENT SITES OF THE SAME TUMOR
    International journal of oncology
    
    B. Fisk et al., "DISSIMILAR TCR V-BETA FREQUENCIES IN TIL FROM DIFFERENT SITES OF THE SAME TUMOR", International journal of oncology, 3(6), 1993, pp. 1111-1120
38. MAYER R; HAN A; FISK B; IOANNIDES CG
    COMMON TCR-BETA CHAIN REARRANGEMENTS IN SHORT-TERM CULTURED LYMPHOCYTES INFILTRATING OVARIAN-TUMORS
    International journal of oncology
    
    R. Mayer et al., "COMMON TCR-BETA CHAIN REARRANGEMENTS IN SHORT-TERM CULTURED LYMPHOCYTES INFILTRATING OVARIAN-TUMORS", International journal of oncology, 2(5), 1993, pp. 851-856
39. IOANNIDES CG; FISK B; JEROME KR; IRIMURA T; WHARTON JT; FINN OJ
    CYTOTOXIC T-CELLS FROM OVARIAN MALIGNANT-TUMORS CAN RECOGNIZE POLYMORPHIC EPITHELIAL MUCIN CORE PEPTIDES
    The Journal of immunology
    
    C.G. Ioannides et al., "CYTOTOXIC T-CELLS FROM OVARIAN MALIGNANT-TUMORS CAN RECOGNIZE POLYMORPHIC EPITHELIAL MUCIN CORE PEPTIDES", The Journal of immunology, 151(7), 1993, pp. 3693-3703
40. IOANNIDES CG; FISK B; FAN D; BIDDISON WE; WHARTON JT; OBRIAN CA
    CYTOTOXIC T-CELLS ISOLATED FROM OVARIAN MALIGNANT ASCITES RECOGNIZE APEPTIDE DERIVED FROM THE HER-2 NEU PROTOONCOGENE/
    Cellular immunology
    
    C.G. Ioannides et al., "CYTOTOXIC T-CELLS ISOLATED FROM OVARIAN MALIGNANT ASCITES RECOGNIZE APEPTIDE DERIVED FROM THE HER-2 NEU PROTOONCOGENE/", Cellular immunology, 151(1), 1993, pp. 225-234